Pemgem is approved by the FDA for the treatment of patients with advanced nonsquamous non-small cell lung cancer (NSCLC), a specific type of NSCLC, to maintain the effect of initial treatment with chemotherapy and whose disease has not worsened. Pemgem is not indicated for patients who have a different type of NSCLC called squamous cell.
Available As: 100 Mg & 500 Mg.